kipesquire.com

Many millions of consumers save substantial amounts of money every single year by using generic anti epilepsy drugs as opposed to brand name versions of the same medications. It has been discovered that the variations in two are so vast that this leads to ineffectiveness, especially when patients choose to change from two alternate generic drugs. This is what is suggested by a novel research effort by Johns Hopkins, this was later published on the internet and in a version of the publication 'Annals Of Neurology', the research has raised new concerns over the safety of some generic medications and their effectiveness.

The research that led to these observations was headed by professor Gregory Krauss, of the Neurology department at the John Hopkins University School of Medicine. The professor and his colleagues made comparisons between the effectiveness of generic medications and brand name medications in addition to different medications that had been made with the use of bioequivalence study information and data that is generated by manufacturers in order to get approval from the FDA.

Dr Gregory says that the range of generic drugs currently on the market may be suitable for the vast majority of pharmaceutical products; nonetheless care should be taken when dealing with 'critical dose' drugs that could be potentially over dosed.

Bioequivalency data for over one hundred and forty one generic epilepsy drugs was secured from the Federal Drug Agency by Krauss and his colleagues with the aid of the freedom of information acts. It was discovered by Krauss that optimal blood concentration and total absorption varied by approximately 15 percent between brand name drugs and their generic counterparts. In conclusion Krauss says that generic medication should be used in the treatment of epilepsy, but pharmacies and patients must exercise caution when deciding to change from different generic versions of drugs categorised as 'anticonvulsants'.